UNLABELLED: Insulin-like growth factors (IGFs) in blood form two complexes with specific binding proteins (BPs): a large, growth hormone (GH)-dependent complex with restricted capillary permeability, and a smaller complex, inversely related to GH, with high turnover of its IGF pool and free capillary permeability. The distribution of BPs and of IGFs I and II between these complexes was studied in sera from healthy adults treated with IGF I or/and GH and from patients with extrapancreatic tumor hypoglycemia. Like GH, IGF I administration raises IGF I and two glycosylation variants of IGFBP-3 in the large complex, but unlike GH drastically reduces IGF II. During IGF I infusion, IGFBP-3 appears in the small complex whose IGFBP-2 and IGF I increase three- to fivefold and fivefold, respectively. GH treatment, associated with elevated insulin levels, suppresses IGFBP-2 and inhibits its increase owing to infused IGF I. The small complex of tumor sera contains increased amounts of IGFBP-2 and -3, and two- to threefold elevated IGF II. CONCLUSIONS: low GH and/or insulin during IGF I infusion and in extrapancreatic tumor hypoglycemia enhance expression of IGFBP-2 and favor partition of IGFBP-3 into the small complex. Free capillary passage and high turnover of its increased IGF I or II pools may contribute to compensate for suppressed insulin secretion during IGF I infusion or to development of tumor hypoglycemia.
UNLABELLED: Insulin-like growth factors (IGFs) in blood form two complexes with specific binding proteins (BPs): a large, growth hormone (GH)-dependent complex with restricted capillary permeability, and a smaller complex, inversely related to GH, with high turnover of its IGF pool and free capillary permeability. The distribution of BPs and of IGFs I and II between these complexes was studied in sera from healthy adults treated with IGF I or/and GH and from patients with extrapancreatic tumor hypoglycemia. Like GH, IGF I administration raises IGF I and two glycosylation variants of IGFBP-3 in the large complex, but unlike GH drastically reduces IGF II. During IGF I infusion, IGFBP-3 appears in the small complex whose IGFBP-2 and IGF I increase three- to fivefold and fivefold, respectively. GH treatment, associated with elevated insulin levels, suppresses IGFBP-2 and inhibits its increase owing to infused IGF I. The small complex of tumor sera contains increased amounts of IGFBP-2 and -3, and two- to threefold elevated IGF II. CONCLUSIONS: low GH and/or insulin during IGF I infusion and in extrapancreatic tumor hypoglycemia enhance expression of IGFBP-2 and favor partition of IGFBP-3 into the small complex. Free capillary passage and high turnover of its increased IGF I or II pools may contribute to compensate for suppressed insulin secretion during IGF I infusion or to development of tumor hypoglycemia.
Authors: J Ballard; R Baxter; M Binoux; D Clemmons; S Drop; K Hall; R Hintz; M Rechler; E Rutanen; J Schwander Journal: Acta Endocrinol (Copenh) Date: 1989-11
Authors: Wenbo Zhi; Ashok Sharma; Sharad Purohit; Eric Miller; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Leigh Steed; Diane Hopkins; Jin-Xiong She Journal: Mol Cell Proteomics Date: 2011-09-06 Impact factor: 5.911
Authors: T Niikura; Y Hashimoto; T Okamoto; Y Abe; T Yasukawa; M Kawasumi; T Hiraki; Y Kita; K Terashita; K Kouyama; I Nishimoto Journal: J Neurosci Date: 2001-03-15 Impact factor: 6.167
Authors: T Horiuchi; Y Shinohara; Y Sakamoto; N Hizuka; T Watabe; O Mokuda; K Tanaka; N Shimizu; I Sugano; K Nagao Journal: Virchows Arch Date: 1994 Impact factor: 4.064
Authors: E Romagnoli; S Minisola; V Carnevale; R Rosso; M T Pacitti; A Scarda; L Scarnecchia; G Mazzuoli Journal: Osteoporos Int Date: 1994-11 Impact factor: 4.507